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1644Objectives: Plasminogen activator inhibitor 1 is the primary regulator of urokinase plasminogen activator and
tissue plasminogen activator. Plasminogen activator inhibitor 1 is essential in the control of the thrombotic/fibri-
nolytic balance and is a marker of endothelial cell injury. Idiopathic dilated cardiomyopathy is reportedly asso-
ciated with endothelial cell dysfunction. Whether endothelial cell damage plays a role in patients with dilated
cardiomyopathy after cardiac transplantation remains unknown.
Methods: In this study explanted hearts of cardiac transplant recipients with ischemic cardiomyopathy and
dilated cardiomyopathy, as well as control myocardial tissue, were investigated for expression of urokinase plas-
minogen activator, tissue plasminogen activator, urokinase plasminogen activator receptor, and plasminogen
activator inhibitor 1 and 2. Furthermore, plasminogen activator inhibitor 1 expression was examined in endomyo-
cardial biopsy specimens and sera of patients with ischemic cardiomyopathy and those with dilated cardiomyop-
athy during the first posttransplantation year. The effect of the patient’s serum on endothelial cells was assessed in
vitro to examine the role of circulating endothelial cell damage–related factors.
Results: Plasminogen activator inhibitor 1 expression was upregulated in ischemic cardiomyopathy and dilated
cardiomyopathy myocardial tissue versus that seen in control tissue. After transplantation, plasminogen activator
inhibitor 1 expression returned to control levels in patients with ischemic cardiomyopathy. In patients with dilated
cardiomyopathy, plasminogen activator inhibitor 1 expression increased at 24 weeks after transplantation in both
biopsy specimens and sera versus that seen in control tissue. Sera of patients with dilated cardiomyopathy, but not
that of patients with ischemic cardiomyopathy, inhibited vascular endothelial growth factor A–induced prolifer-
ation of endothelial cells, although downstream target gene activation of early growth response factor 1 and
NGFI-A binding protein 2 was not affected.
Conclusions: These data suggest for the first time that the endothelial cell damage–related process recurs in patients
with dilated cardiomyopathy after transplantation, which, independently of vascular endothelial growth factor, is as-
sociated with increased plasminogen activator inhibitor 1 expression, and that this pathology might play a role in al-
lograft remodeling in patients with dilated cardiomyopathy. (J Thorac Cardiovasc Surg 2010;139:1644-51)Plasminogen activator inhibitor (PAI) 1 is a key regulator of
the plasminogen activation system, a proteolytic cascade im-
plicated in various physiological and pathophysiological pro-
cesses, including vascular thrombolysis, inflammation, wound
healing, tumor invasion, and neovascularization.1 PAI-1 is the
primary regulator of the plasminogen activators urokinase
plasminogen activator (uPA) and tissue plasminogen activator
(tPA) and is essential in control of the physiological throm-
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The Journal of Thoracic and Cardiovascular Surpathways are also essential in the development of various car-
diovascular diseases.3-5 A second inhibitor of the plasminogen
activation system is PAI-2, the biologic role of which in the
cardiovascular system is unclear. Only in tumor biology has
PAI-2 been shown to play the opposite role versus PAI-1.6
Epidemiologic studies have indicated that high plasma
levels of PAI-1 constitute a risk factor for ischemic heart
disease caused by impaired thrombolysis and have also
been associated with atherosclerosis by affecting matrix
remodeling.3 PAI-1 is expressed by various cell types,
including endothelial cells (ECs), smooth muscle cells,
fibroblasts, inflammatory cells, and platelets,2 and is upregu-
lated by inflammatory cytokines, such as interleukin 1,
tumor necrosis factor a, or transforming growth factor
(TGF) b.3 Apart from the intravascular compartment, PAI-
1 is also present in the subendothelial extracellular matrix
(ECM), where it controls local proteolysis through inhibition
of plasminogen activators and orchestrates cell adhesion and
migration through interaction with integrins and ECM com-
ponents. Increased PAI-1 production and a subsequent in-
crease in thrombogenicity are important components ofgery c June 2010
Abbreviations and Acronyms
DCM ¼ dilated cardiomyopathy
EC ¼ endothelial cell
ECM ¼ extracellular matrix
EGR ¼ early growth response
ET ¼ endothelin
HDMVEC ¼ human dermal microvascular
endothelial cells
ICM ¼ ischemic cardiomyopathy
NAB ¼ NGFI-A binding protein
PAI ¼ plasminogen activator inhibitor
TGF ¼ transforming growth factor
tPA ¼ tissue plasminogen activator
uPA ¼ urokinase plasminogen activator
uPAR ¼ urokinase plasminogen activator
receptor
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Scha¨fer et al Cardiothoracic Transplantationendothelial dysfunction.7 The interplay between PAI-1 and
ECs is critical for angiogenesis, and this process is primarily
mediated through uPA–antiproteinase interactions.2
Regulators of ECM composition and EC survival, such as
endothelin (ET) 1 and TGF-b, are key factors that are dysre-
gulated in patients with idiopathic dilated cardiomyopathy
(DCM),8,9 and in combination with PAI-1, they can reflect
the extent of endothelial damage.10 DCM, similar to ischemic
cardiomyopathy (ICM), is one of the leading causes of heart
failure in patients undergoing cardiac transplantation. It has
been demonstrated that PAI-1 activity in the blood of heart
transplant recipients increases at 6 months after transplanta-
tion,11 and the resulting hypofibrinolytic condition has been
discussed as a risk factor of allograft vasculopathy.11,12 The
issue of whether and how the uPA/uPA receptor (uPAR)/
PAI-1 system affects ECM-related homeostasis and EC sur-
vival in cardiac allografts in patients with DCM has remained
unclear. We addressed this issue.T
XMATERIALS AND METHODS
Patients and Tissue Sampling
In this study, which was approved by the Ethics Committee of the Med-
ical University of Vienna, a total of 84 patients with heart failure who pro-
vided informed consent to be enrolled, including those with idiopathic DCM
(n ¼ 60) and ICM (n ¼ 24), were studied. All patients had been scheduled
for cardiac transplantation between 1999 and 2003 and provided informed
consent to be enrolled. The control group consisted of 12 donors with no
history of cardiac disease whose hearts could not be transplanted for quality
reasons. Table 1 summarizes the demographic and most important clinical
data of the patients. Patients with myocardial infarction (6 months before
surgical intervention) or echocardiographic evidence of valvular diseases
caused by ischemic heart disease were excluded from the study. Patients
with idiopathic DCM were routinely screened for the (unlikely) presence
of coronary artery disease, and the patients with DCM included in the pres-
ent study were free from coronary artery disease. Multiple myocardial bi-The Journal of Thoracic and Caropsy specimens were taken from the anterior aspect of the left ventricle.
The selection criteria for final inclusion of the biopsy specimens into the
study were preoperative, as follows. Biopsy specimens were taken 2 cm dis-
tal to the diagonal branch and 2 cm from the left anterior descending coro-
nary artery. If the left anterior descending coronary artery was occluded,
resulting in myocardial infarction and scarring as confirmed by means of
coronary angiographic and echocardiographic analysis, the patient was ex-
cluded from the study. These preoperative criteria helped us to differentiate
between necrotic or scar tissue (excluded) and ischemic myocardium (in-
cluded into this study). Endomyocardial biopsy specimens from the grafted
hearts and serum samples were obtained at 1, 2, 3, 4, 6, 12, 24, and 52 weeks
after transplantation and snap-frozen for molecular analyses. Table 2 shows
pretransplantation and posttransplantation medication, as well as the immu-
nosuppression regimen of the study patients.
Real-Time Reverse Transcription Polymerase Chain
Reaction
RNA was isolated from myocardial tissue, and polymerase chain reaction
was performed, as previously described.13 The primer sequences used
for target genes were as follows (sense/antisense): uPA, 50-CCAGTTTGGCA
CAAGCTG-30/50-GAGACTCTCGTGTAGACG-30; tPA, 50-CGACAAT
GACATTGCGCT-30/50-CACAGCATGTTGTCGG-30; uPAR, 50-CAGTGT
TACAGCTGCAAG-30/50-CACTTTTAGTACAGCAGG-30;PAI-1, 50-GGA
AAGGCAACATGACCA-30/50-GAGACTATGACAGCTGTG-30; PAI-2,
50-CCAGCAAAGACAAAATGGC-30/50-CCCTGTCATAACACCTCC-30;
early growth response (EGR) 1, 50-AGGACAAGAAAGCAGACAAAAG-
30/50-ATAAGAGGTAGTAACCGGGGAC-30; NGFI-A binding protein
(NAB) 2: 50-TGGTGGAAAGTGTGGAGAGG-30/50-CGAAACGGCCATA
GATGATG-30; TGFB: 50-ATGACAAGTTCAAGCAGAG-30/50-CACTTG
CAGTGTGTTATCC-30; ET-1, 50-GGAAAAGACTGTTCCAAGC-30/50-G
GTTGTGGGTCACATAACG-30; and b2-microglobulin, 50-GATGAGTAT
GCCTGCCGTGTG-30/50-CAATCCAAATGCGGCATCT-30. LCDA Ver-
sion 3.1.102 software (Roche, Mannheim, Germany) was used for polymerase
chain reaction data analysis. The specificity of the amplification product was
determined by performing a melting curve analysis. Standard curves for
expression of each gene were generated by serial dilution of known quantities
of the respective cDNA gene template. Relative quantification of the signals
was done by normalizing the signals of the different genes with the b2-micro-
globulin signal. Measurements were done in triplicate.
Western Blotting
Tissue was solubilized, and Western blotting was performed, as previ-
ously described.13 The blots were probed with antibodies against uPA
(mouse monoclonal; Oncogene, Darmstadt, Germany) and PAI-1 (rabbit
polyclonal; Santa Cruz, Santa Cruz, Calif) before incubation with horserad-
ish peroxidase–conjugated secondary antibodies (Amersham, Buckingham-
shire, United Kingdom). Proteins were immunodetected on the membrane
by using chemiluminescence (Supersignal-West-Femto; Pierce, Rockford,
Ill), and specific protein bands were quantified with Easy plus Win 32 soft-
ware (Herolab, Wiesloch, Germany).
Organ Culture
Freshly isolated myocardial tissue (approximately 2–3 mm3) from pa-
tients with DCM and ICM was incubated in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum, as previously described.13 Six
hours after isolation, wells were stimulated with 100 ng/mL vascular endo-
thelial growth factor (VEGF) A (Promokine, Heidelberg, Germany), fol-
lowed by incubation for 24 hours and RNA isolation. Experiments were
performed in triplicate. Additionally, aortic ECs, smooth muscle cells,
and cardiomyocytes were isolated for RNA analyses.8,9
EC Culture
Human dermal microvascular endothelial cells (HDMVECs) were cul-
tured in EGM-2 MV medium (Lonza, Basel, Switzerland) plus 10% fetaldiovascular Surgery c Volume 139, Number 6 1645
TABLE 1. Demographic and selected echocardiographic data and
posttransplantation outcome parameters of patients
Controls
(n ¼ 12)
ICM
(n ¼ 24)
DCM
(n ¼ 60)
Pretransplantation
parameters
Age, y 41  7 49  6 47  4
Sex, M/F 10/2 20/4 34/26
NYHA class, III/IV  14/10 38/22
Body surface area, m2 1.81  0.14 1.83  0.14 1.81  0.20
LVEDDI, mm/mm2 25.6  1.7 37.8  3.9* 45.0  7.1*,y
LVEDV, mL 64  2 177  9* 284  10*,y
Ejection fraction,% 72  6 22  7* 18  6*
Cardiac index,
L/m2 3 min1
3.09  0.28 2.14  0.41* 2.01  0.38*
Mean PAP, mm Hg 15.5  2.0 27.8  6.8* 34.7  10.1*
PCWP, mm Hg 4.6  1.4 20.4  5.4* 21.0  6.8*
Outcome parameters
3-mo Mortality  12.5% 13.3%
1-y Mortality  20.8% 13.3%
5-y Mortality (n¼ 76)  21.1% (n ¼ 19) 20.8% (n ¼ 48)
Rejection (>grade 0)
incidence in 3-mo
survivors in first
posttransplantation
year
 41.7% 50.0%
Cardiac allograft
vasculopathy
incidence in 3-mo
survivors, 5 y after
transplantation
(n ¼ 65)
 11.8% (n ¼ 17) 12.5% (n ¼ 40)
ICM, Ischemic cardiomyopathy; DCM, dilated cardiomyopathy; NYHA, New York
Heart Association; LVEDDI, left ventricular end-diastolic diameter index; LVEDV,
left ventricular end-diastolic volume; PAP, pulmonary arterial pressure; PCWP, pul-
monary capillary wedge pressure. *P< .05 versus control subjects. yP< .05 versus
patients with ICM.
TABLE 2. Pretransplantation and posttransplantation medication of
the study patients
Characteristic
All
patients
(n ¼ 93)
Patients
with DCM
(n ¼ 60)
Patients
with ICM
(n ¼ 24)
Diabetes mellitus
Absent 44 27 13
IDDM 12 9 3
NIDDM 37 24 8
Pretransplantation medication
Statin, yes/no 32/61 11/49 19/5
ACE inhibitor, yes/no 69/24 44/16 20/4
AT II receptor
inhibitor, yes/no
24/69 17/43 5/19
PGE, yes/no 29/64 19/41 8/16
Digitalis, yes/no 40/53 32/28 6/18
Coumarin, yes/no 61/32 40/20 17/7
Amiodarone, yes/no 39/54 33/27 4/20
b-blocker, yes/no 72/21 46/14 21/3
Nitroglycerine, yes/no 10/83 5/55 5/19
Posttransplantation medication
ACE inhibitor, yes/no 26/68 15/45 8/16
Statin, yes/no 55/38 30/30 20/4
Immunosuppression*
Cyclosporineþazathioprine 9 6 3
Tacrolimusþazathioprine 2 1 1
Cyclosporineþmycophenolate
mofetil
47 29 12
Tacrolimusþmycophenolate
mofetil
16 9 6
Cyclosporineþeverolimus 5 3 1
Other combinations 14 12 1
DCM, dilated cardiomyopathy; ICM, Ischemic cardiomyopathy; IDDM, insulin-
dependent diabetes mellitus; NIDDM, non–insulin-dependent diabetes mellitus;
ACE, angiotensin converting enzyme; AT, angiotensin; PGE, prostaglandin E. *All
patients received steroids, as previously described.8
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Xbovine serum. Cells were isolated, as previously described.8 HDMVECs
were grown in EGM-2 MV medium supplemented with serum from patients
with DCM and ICM and healthy control subjects for 24 and 48 hours and
then stimulates with 100 ng/mL recombinant VEGF-A (Promokine) for
45 minutes, followed by RNA and protein isolation. Experiments were per-
formed in triplicate.
Proliferation Assay
HDMVECs were seeded on 96-well plates at a density of 10,000 cells per
well in EGM-2 MV supplemented with 10% fetal bovine serum. Culture
medium was replaced with EGM-2 MV medium supplemented with serum
(before transplantation and 4 and 52 weeks after transplantation) from patients
with DCM and ICM and healthy control subjects and then stimulated with
100 ng/mL recombinant VEGF-A (Promokine). The cultures were maintained
for an additional 24 or 48 hours for each treatment and time point in quadru-
plicate. Cell proliferation was determined by using the WST-1 reagent (Roche
Diagnostics, Indianapolis, Ind), according to the manufacturer’s protocol.14
Data Analysis
We used analysis of variance with the Bonferroni post hoc test and the
Wilcoxon rank test to compare the data between the groups. Regression
analysis was performed to assess differences among the time points of pa-1646 The Journal of Thoracic and Cardiovascular Surtients with DCM and ICM undergoing transplantation. All statistical tests
were 2-sided. Data are expressed as means standard deviations. Statistical
tests were performed with the use of SPSS software (version 10.0.7; SPSS,
Inc, Chicago, Ill).RESULTS
Selective Upregulation of PAI-1 mRNA and Protein
Expression in Patients With DCM
The myocardial mRNA expression of uPA, tPA, uPAR,
and PAI-2 was unchanged in both patient groups, whereas
myocardial mRNA expression of PAI-1 was significantly
upregulated in patients with DCM and ICM versus that
seen in control subjects (P< .05; Figure 1, A). The protein
expression of pro and active uPA was unchanged in both pa-
tients with DCM and those with ICM compared with that
seen in control myocardial biopsy specimens. Only in pa-
tients with DCM was pro PAI-1 and PAI-1 protein expres-
sion significantly increased compared with that seen in
control subjects (P< .05; Figure 1, B).gery c June 2010
FIGURE 1. A, Quantification of mRNA expression levels of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), urokinase plasmin-
ogen activator receptor (uPAR), and plasminogen activator inhibitor (PAI) 1 and 2 in cardiac biopsy specimens of control subjects and patients with dilated
cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). B, Quantification of protein expression levels of pro uPA, active uPA, latent PAI-1, and active
PAI-1 in cardiac biopsy specimens of control subjects and patients with DCM and ICM. Results are expressed as means  standard deviations. *P< .05
compared with control subjects.
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XPAI-1 Expression Increases 24 Weeks After Heart
Transplantation in Patients With DCM
We followed the mRNA expression pattern of PAI-1 in
cardiac grafts of patients with DCM and ICM for 1 year after
transplantation. In myocardial biopsy specimens obtained
from patients with ICM who underwent transplantation,
PAI-1 mRNA levels were not significantly different versus
those of control subjects during the follow-up period. In con-
trast, PAI-1 mRNA expression was significantly increased
in grafted hearts of patients with DCM compared with that
seen in control subjects at 24 and 52 weeks after transplan-
tation, although PAI-1 mRNA expression levels were not
significantly different from those of control subjects at 1 to
12 weeks after transplantation (Figure 2, A).
Changes in PAI-1 serum concentrations were less striking
than changes in myocardial tissue expression levels. How-
ever, the trend toward upregulated PAI-1 expression in pa-
tients with DCM at 24 and 52 weeks after transplantation
was also present in serum. In patients with ICM and
DCM, PAI-1 pretransplantation serum concentrations were
not significantly different from those of control subjects.The Journal of Thoracic and CarAfter heart transplantation in patients with ICM, PAI-1 se-
rum concentrations increased until week 3 compared with
pretransplantation levels. At week 4, PAI-1 serum levels
decreased in patients with ICM and remained stable there-
after at slightly higher levels than in control subjects
(Figure 2, B). In contrast, in patients with DCM, PAI-1 se-
rum levels increased after cardiac transplantation and re-
mained upregulated during the first postoperative year
compared with pretransplantation levels and levels seen in
control subjects (P< .05; Figure 2, B). These data indicated
differentially expressed PAI-1 levels after transplantation in
patients with ICM compared with those seen in patients
with DCM.
PAI-1 Expression Is Independent of VEGF
Stimulation with VEGF-A in DCM and ICM cardiac tis-
sue cultures did not affect uPAR and PAI-1 expression,
whereas uPA expression was upregulated in DCM and
ICM versus untreated tissue cultures (Figure 3, A). These ex-
periments demonstrated that PAI-1 expression is indepen-
dent of VEGF in DCM and ICM cardiac tissue cultures.diovascular Surgery c Volume 139, Number 6 1647
FIGURE 2. A, Quantification of plasminogen activator inhibitor (PAI-1) mRNA expression in cardiac biopsy specimens at 1 to 52 weeks after heart trans-
plantation in patients with dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). B, Quantification of PAI-1 serum levels at 1 to 52 weeks after
heart transplantation of patients with DCM and ICM. Results are expressed as means standard deviations. *P<.05 compared with control subjects. yP<.05
compared with patients with ICM.
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cardiomyocytes from cardiac tissue express PAI-1, ET-1
and TGFB (Table 3).FIGURE 3. A, Vascular endothelial growth factor (VEGF) stimulation in orga
ischemic cardiomyopathy (ICM). Quantification of mRNA expression of urokin
(uPAR), and plasminogen activator inhibitor (PAI) 1 is shown. B, Endothelial cell
ICM for 24 and 48 hours. Quantification of protein expression of PAI-1 is shown
with control subjects.
1648 The Journal of Thoracic and Cardiovascular SurRole of Patients’ Sera in EC Activation In Vitro
Because PAI-1 is involved in EC damage and because its
serum levels increase in patients with DCM aftern cultures isolated from patients with dilated cardiomyopathy (DCM) and
ase plasminogen activator (uPA), urokinase plasminogen activator receptor
s incubated with sera obtained from control subjects or patients with DCM or
. Results are expressed as means  standard deviations. *P<.05 compared
gery c June 2010
TABLE 3. Expression of PAI-1, ET-1, and TGF-b in different cardiac
cell types
PAI-1 ET-1 TGF-b
Endothelial cells þ þ þ
Smooth muscle cells þ þ þ
Cardiomyocytes þ þ þ
PAI-1, Plasminogen activator inhibitor 1; ET-1, endothelin 1; TGF-b, transforming
growth factor b.
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with DCM on VEGF-stimulated ECs.
Incubation of ECs with sera obtained from control sub-
jects, patients with DCM, or patients with ICM does not af-
fect basal protein expression of PAI-1 after 24 hours.
However, after 48 hours, PAI-1 protein expression increases
significantly (P< .05) in ECs cultured with sera obtained
from patients with DCM (Figure 3, B). These results desig-
nate that sera obtained from patients with DCM influence the
expression level of PAI-1 in ECs.Sera of Patients With DCM Block EC Proliferation
Stimulation of ECs with recombinant VEGF-A increased
the cell proliferation rate when the ECs were cultured withFIGURE 4. In vitro stimulation with vascular endothelial growth factor (VEGF)
with dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). A, Q
cultured with patients’ pretransplantation sera. B, Quantification of proliferation
obtained 4 and 52 weeks after transplantation. Results are expressed as means 
The Journal of Thoracic and Carmedium containing sera obtained from patients with ICM
(before transplantation and 4 and 52 weeks after transplanta-
tion) or control subjects (P< .05). In contrast, stimulation
with recombinant VEGF-A did not stimulate EC prolifera-
tion in ECs cultured with sera obtained from patients with
DCM (before transplantation and 4 and 52 weeks after trans-
plantation, Figure 4). These results indicate that sera of pa-
tients with DCM block VEGF-induced EC proliferation.
VEGF Induces Signaling Target Genes in the
Presence of Sera From Patients With ICM and DCM
Stimulation of ECs cultured with medium containing sera
obtained from patients with DCM and ICM or control sub-
jects and supplemented with recombinant VEGF-A upregu-
lated significantly the mRNA expression of 2 target genes of
the VEGF signaling pathway: EGR-1 (P< .05) and NAB-2
(P< .05; Figure 5). These experiments demonstrate that
the VEGF signaling through its receptor was still inducible
independent of patients’ sera.
DISCUSSION
The results presented here were mainly based on post-
transplantation mRNA levels, which might be a limitation.A of endothelial cells cultured with serum from control subjects and patients
uantification of VEGF-A–stimulated cell proliferation of endothelial cells
in endothelial cells stimulated with VEGF-A cultured with patient serum
standard deviations. *P< .05 compared with control subjects.
diovascular Surgery c Volume 139, Number 6 1649
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FIGURE 5. Quantification of mRNA expression of vascular endothelial growth factor (VEGF) target genes (EGR-1 and NAB-2) in VEGF-A–stimulated
endothelial cells cultivated with patients’ sera. Results are expressed as means standard deviations. *P<.05 compared with control subjects. DCM, Dilated
cardiomyopathy; ICM, ischemic cardiomyopathy.
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tein expression is nearly impossible because of the critically
small size of endomyocardial biopsy specimens. The
increased serum PAI-1 levels might indicate a general re-
sponse to ischemia and reperfusion, and early expression
of PAI-1 has been shown to protect against intimal prolifer-
ation associated with development of allograft vasculopathy
in an experimental setting.15 The increasing and then persist-
ing PAI-1 mRNA expression associated with its serum
changes in patients with DCM might postulate a systemic
hypofibrinolytic condition in cardiac transplant recipients
with idiopathic DCM, and this condition becomes prominent
at 6 months after transplantation.12,16 However, it must be
noted that serum PAI-1 levels might not be fully representa-
tive of local (myocardial tissue) expression levels.
Several immunosuppressive drugs that are generally ap-
plied in cardiac transplant recipients have an effect on the ex-
pression of PAI-1. For example, steroid treatment has been
related to increased serum PAI-1 levels independent of diag-
nosis.17 However, this might not play a role in the present
study because all patients received steroid treatment as one
part of their immunosuppressive regimen and no steroid-
free protocols were applied. Moreover, the influence of cy-
closporine or tacrolimus on PAI-1 serum levels might not
be determined in this study because both protocols were ap-
plied irrespective of diagnosis in patients with ICM and
DCM (Table 2). Posttransplantation statins were more fre-
quently applied in patients with ICM than in patients with
DCM, whereas angiotensin-converting enzyme inhibitors
were applied in a similar percentage of patients in each dis-
ease group. Patients with valvular heart diseases (data not
shown), who did not receive posttransplantation statins as
frequently as patients with ICM patients, had a similar pat-
tern of PAI-1 expression at 24 and 52 weeks after transplan-
tation compared with that seen in patients with ICM. Because
statins reportedly decrease PAI-1 expression,18 we cannot
exclude that the PAI-1 results presented in our study might
have been influenced by dissimilar use of statins.1650 The Journal of Thoracic and Cardiovascular SurPAI-1, in combination with ET-1 and TGF-b, are known
indicators of EC damage,7,10 and PAI-1 and ET-19 expression
levels increase in endomyocardial biopsies of patients with
DCM at 6 and 12 months after transplantation. TGF-b is
involved in inflammatory reactions and in tissue remodeling,
exerting its effects on composition of the ECM through
expression of matrix metalloproteases.9,19 Moreover, TGF-b
regulates PAI-1 expression through the mitogen-activated
protein kinase kinase extracellular signal-regulated kinase
pathway.19 However, in patients with DCM, TGF-b expres-
sion does not change in cardiac allografts after transplanta-
tion,9 so that PAI-1 expression in cardiac allografts of
patients with DCM is apparently regulated independent of
the TGF-b signaling pathway.
Both ET-1 expression9 and PAI-1 expression increase at 6
months after transplantation, particularly in patients with
DCM. ET-1 and PAI-1 are primarily expressed by nonmyo-
cytes, particularly ECs and fibroblasts, and this might indicate
a persisting pathology in patients with DCM undergoing car-
diac transplantation that is not confined to the myocardium.
This is further underlined by the result that pretransplantation
and posttransplantation sera of patients with DCM inhibited
VEGF-A–induced EC proliferation, although the intracellular
signaling cascade for VEGF-A was responding. These find-
ings suggest that a strong antiproliferative stimulus that is
not yet identified and that acts independently of VEGF-A sig-
naling is present in the sera of patients with DCM. In combi-
nation with ET-1, increased PAI-1 expression starting at 6
months after transplantation in patients with DCM might af-
fect myocardial tissue remodeling, with increased ECM depo-
sition and EC damage in the context of cardiac allograft
fibrosis and microvascular remodeling in patients with DCM.
However, the molecular pathology described above
should be considered with caution because in the posttrans-
plantation setting patients with idiopathic DCM reveal no
clinical peculiarities when compared with patients with
ICM. In addition, patients with DCM have not been reported
to have a shorter survival or more frequent events aftergery c June 2010
Scha¨fer et al Cardiothoracic Transplantationtransplantation compared with other patients with heart fail-
ure undergoing heart transplantation. However, it must be
noted that the present study has served to further illuminate
the previously identified vascular pathology in patients with
DCM8,9,13 and to explain that in patients with DCM an
additional, PAI-related but VEGF-independent system is op-
erating that could contribute to this molecular pathology.
Delineating how the molecular pathology identified in the
present study might affect long-term clinical outcome in
heart transplant recipients, particularly with regard to graft
coronary artery vasculopathy,12 calls for randomized pro-
spective studies, which are being planned currently in our
center. Such studies might consider the fact that upregulated
PAI-1 levels are associated with a poor prognosis in many
cancer types and have been even considered as a prognostic
marker in malignant diseases.6 Finally, we might specifi-
cally refer to the point that the observed pathology of the
PAI-1 system in this study could have been considered
DCM unspecific. However, the results on PAI-1 in patients
with heart failure due to valvular diseases point to the fact
that the results are DCM specific and in line with our previ-
ous observations,8,9,19 suggesting a vascular-related pathol-
ogy for idiopathic DCM.References
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